New drug cocktail aims to shrink tough stomach and esophageal tumors
NCT ID NCT06247956
Summary
This study is testing a new three-drug combination for people with advanced stomach or esophageal cancer who haven't had prior treatment. It combines an experimental immunotherapy drug (SHR-8068) with an approved immunotherapy (adebrelimab) and standard chemotherapy. The main goal is to see how well this combination shrinks tumors in 153 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA AND ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Conditions
Explore the condition pages connected to this study.